Nicholas A. Saccomano is currently the CEO of OnKure therapeutics, a precision oncology company in Boulder Colorado.  He is a biopharmaceutical professional with more than 35 years of extensive research, development and management experience across multiple therapeutic areas. He most recently worked at Pfizer R&D, Inc. as Chief Science Officer and Site Head at its Boulder facility, where he led a 170-person research and development team that advanced a portfolio of small molecule drug programs from inception to proof-of-concept. Prior to working at Pfizer, Dr. Saccomano served as Chief Science Officer at Array Biopharma Inc., where he led and contributed to the teams that created and advanced ten clinical-stage compounds, with seven drug approvals to date. Dr. Saccomano also served as Chief Technology Officer at SomaLogic Inc., where he managed scientific and technical teams in charge of advancing elements of the company’s proteomic platform. He currently serves as a scientific advisor or board member to several innovative companies. Dr. Saccomano received a B.S. from the State University of New York at Buffalo and a Ph.D. in Organic Chemistry from Columbia University under the direction of Professor Gilbert Stork.